CTOs on the Move

ANI Pharmaceuticals

www.anipharmaceuticals.com

 
ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Funding

ANI Pharmaceuticals raised $125M on 12/29/2017
ANI Pharmaceuticals raised $75M on 11/03/2021

Similar Companies

GFS Chemicals

GFS Chemicals is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sentrol

Sentrol is a Plymouth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syner-G BioPharma Group

Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company`s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Montana Health Research Inst

Montana Health Research Inst is a Billings, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.